Aroa Biosurgery (ASX:ARX) PE Ratio without NRI: 50.00 (As of Jun. 29, 2026) — 11% Below Median


ASX:ARX Aroa Biosurgery Ltd ASX:ARX
64 GF Score
Price A$0.60
GF Value A$0.80
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Aroa Biosurgery PE Ratio without NRI?

Aroa Biosurgery ASX:ARX +1.69% 64 PE Ratio without NRI is 50.00 as of Jun. 29, 2026, which is 11% below its 10-year median of 56.36. GuruFocus rates ASX:ARX with a GF Score™ of 64/100 and a GF Value™ of A$0.80 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 446 Medical Devices & Instruments companies, Aroa Biosurgery ranks worse than 81.61% on this metric.

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-06-29), Aroa Biosurgery's share price is A$0.60. Aroa Biosurgery's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was A$0.01. Therefore, Aroa Biosurgery's PE Ratio without NRI for today is 50.00.

During the past 7 years, Aroa Biosurgery's highest PE Ratio without NRI was 63.18. The lowest was 47.73. And the median was 56.36.

Aroa Biosurgery's EPS without NRI for the six months ended in Mar. 2026 was A$0.02. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was A$0.01.

As of today (2026-06-29), Aroa Biosurgery's share price is A$0.60. Aroa Biosurgery's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was A$0.01. Therefore, Aroa Biosurgery's PE Ratio (TTM) for today is 50.00.

During the past years, Aroa Biosurgery's highest PE Ratio (TTM) was 63.18. The lowest was 47.73. And the median was 56.36.

Aroa Biosurgery's EPS (Diluted) for the six months ended in Mar. 2026 was A$0.02. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was A$0.01.

Aroa Biosurgery's EPS (Basic) for the six months ended in Mar. 2026 was A$0.02. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was A$0.01.


Aroa Biosurgery  (ASX:ARX) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


Aroa Biosurgery PE Ratio without NRI Related Terms


Aroa Biosurgery PE Ratio without NRI Historical Data

* Premium members only.

The historical data trend for Aroa Biosurgery's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aroa Biosurgery PE Ratio without NRI Chart

Aroa Biosurgery Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
PE Ratio without NRI
Get a 7-Day Free Trial At Loss At Loss At Loss At Loss 54.09

Aroa Biosurgery Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss 54.09

ASX:ARX vs ABT, SYK, MDT: PE Ratio without NRI Comparison

For the Medical Devices subindustry, Aroa Biosurgery's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aroa Biosurgery PE Ratio without NRI vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Aroa Biosurgery's PE Ratio without NRI falls into.


ASX:ARX
64GF Score
Aroa Biosurgery Ltd ASX:ARX
PE Ratio without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aroa Biosurgery PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

Aroa Biosurgery's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=0.60/0.012
=50

Aroa Biosurgery's Share Price of today is A$0.60.
For company reported semi-annually, Aroa Biosurgery's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio without NRI →
What does a PE Ratio without NRI of 50.00 mean?
Aroa Biosurgery (ASX:ARX) has a PE Ratio without NRI of 50.00 as of Jun. 29, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Aroa Biosurgery and its competitors. This is 11% below median its historical median of 56.36. Over the past decade, Aroa Biosurgery's PE Ratio without NRI has ranged from 47.73 to 63.18. According to the industry distribution chart, Aroa Biosurgery ranks #364 out of 446 companies in the Medical Devices & Instruments industry, placing it in the top 81.6%.
Is Aroa Biosurgery's PE Ratio without NRI too high?
Aroa Biosurgery's current PE Ratio without NRI of 50.00 is 11% below median its 10-year median of 56.36. Over the past 10 years, this metric has ranged from a low of 47.73 to a high of 63.18. The Medical Devices & Instruments industry median PE Ratio without NRI is 23.18. Aroa Biosurgery's value of 50.00 is 115.7% above this industry median. Based on the distribution chart, Aroa Biosurgery ranks #364 out of 446 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Aroa Biosurgery has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's PE Ratio without NRI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Aroa Biosurgery ranks #364 out of 446 companies for PE Ratio without NRI. This places Aroa Biosurgery in the lower half of its industry. The industry median PE Ratio without NRI is 23.18. Aroa Biosurgery's value of 50.00 is 115.7% above this benchmark. Historically, Aroa Biosurgery's own PE Ratio without NRI has ranged from 47.73 to 63.18 over the past decade. While the company's 10-year median is 56.36 vs. the industry median of 23.18, Aroa Biosurgery has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Medical Devices & Instruments company?
The median PE Ratio without NRI among Medical Devices & Instruments companies is 23.18, based on 446 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aroa Biosurgery's current PE Ratio without NRI of 50.00 is 115.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Aroa Biosurgery and its competitors. For the Medical Devices & Instruments industry, the median PE Ratio without NRI is 23.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aroa Biosurgery's current PE Ratio without NRI is 50.00, which is 11% below median its own 10-year median of 56.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (ASX:ARX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.80, compared to a current price of A$0.60 — trading 25% below its estimated fair value. The current PE Ratio without NRI is 50.00, which is 11% below median its 10-year median of 56.36 and 115.7% above the Medical Devices & Instruments industry median of 23.18. Aroa Biosurgery's overall GF Score™ is 64/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Aroa Biosurgery (ASX:ARX), the current PE Ratio without NRI is 50.00 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aroa Biosurgery (ASX:ARX) Overvalued in 2026?

Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued. The current stock price of A$0.60 is trading 25% below its estimated GF Value™ of A$0.80. GuruFocus considers Aroa Biosurgery to be Modestly Undervalued.

Key valuation signals for ASX:ARX:

  • PE Ratio without NRI: 50.00 (11% below median its 10-year median of 56.36)
  • GF Value™: A$0.80 vs. price of A$0.60 (25% below fair value)
  • GF Score™: 64/100 with 1 warning sign
  • Industry Position: 115.7% above the Medical Devices & Instruments median (#364 of 446)

No single metric tells the full story. See the ASX:ARX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aroa Biosurgery Business Description

Other Exchanges AROAF:USA
Address 64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
64GF Score

Get the complete analysis for ASX:ARX

PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.60
Price
A$0.80
GF Value